Matthew Sleeman is the Executive Director of Immunology & Inflammation at Regeneron Pharmaceuticals. This team supports the development of novel biologic therapies for the treatment of a range of different allergic and autoimmune diseases, such as atopic dermatitis, asthma and rheumatoid arthritis. In addition to this the group works closely with Oncology to develop new immunotherapeutic approaches for cancer. Prior to joining Regeneron Matt Sleeman was a Senior Director of Biology for the Respiratory, Inflammation and Autoimmunity Group at MedImmune in Cambridge UK and also held several positions within Cambridge Antibody Technology (CAT). Before working in the antibody field, he worked for a New Zealand start up Genesis Research & Development isolating and characterizing novel growth factors and cytokines. Matt Sleeman holds a PhD from the University of Durham, UK.